With Duchenne muscular dystrophy affecting thousands of patients worldwide and no curative option currently available, the market for Exondys 51 — a key exon-skipping therapy — is drawing fresh attention from investors and healthcare providers alike. A new forecast from The Business Research Company lays out where this niche but vital pharmaceutical segment is headed through 2035.
The Business Research Company’s Exondys 51 Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
The Exondys 51 market is attracting growing interest as breakthroughs in genetic medicine and rising healthcare spending open new doors. With personalized therapies for rare genetic conditions such as Duchenne muscular dystrophy (DMD) moving to the forefront, the sector is projected to see meaningful expansion. Here’s a closer look at the market’s current valuation, the forces driving its growth, regional patterns, and the trends likely to define its trajectory.
Also worth a look: Las Vegas CES photographer Christian Purdie rolls out real-time photo delivery for exhibitors and SJC Media’s Wonder takes event expertise beyond its own brands with new managed services.
Historical performance and future projections for the Exondys 51 market
In prior years, market growth was fueled largely by the lack of any cure for DMD, reliance on supportive treatment methods, early-stage antisense research, regulatory incentives for rare disease therapies, and initial approvals. Going forward, the sector is expected to benefit from advances in molecular genetics, the expansion of personalized neuromuscular care, wider newborn screening initiatives, increased research funding for DMD, and the growth of specialized neurology centers. Notable developments on the horizon include broader adoption of exon skipping approaches, a more diverse pipeline of targeted DMD therapies, growing use of gene-based treatments, and a stronger emphasis on delaying disease progression and improving long-term patient management.
Download a free sample of the exondys 51 market report:
https://thebusinessresearchcompany.com/sample_request?id=31248132&type=smp&name=Exondys%2051%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
How Exondys 51 works in the fight against DMD
Exondys 51, also known as eteplirsen, is a medication engineered to treat Duchenne muscular dystrophy by inducing exon skipping of exon 51 in the dystrophin gene. This approach enables the body to generate a shorter yet still functional version of the dystrophin protein, helping to slow the breakdown of muscle tissue. By effectively bypassing the defective portion of the gene, Exondys 51 allows patients to produce a protein variant that supports better muscle performance despite the underlying mutation.
Genetic disorder rates pushing demand upward
The rising incidence of genetic disorders is a major factor driving global demand for Exondys 51. These conditions, caused by DNA mutations or abnormalities, are being identified more frequently thanks to improved medical technologies, shifting demographics, and greater diagnostic capabilities and public awareness. In the case of DMD, Exondys 51 tackles the root genetic issue by promoting exon 51 skipping, which leads to the production of a working dystrophin protein and less severe muscle deterioration. For context, in July 2024, the UK’s National Health Service noted that roughly 70,000 people in the UK live with muscular dystrophy or related conditions, with DMD being the most prevalent. Around 100 boys are diagnosed with DMD each year, and about 2,500 individuals in the UK are currently living with the disease — numbers that underscore the substantial patient base fueling market growth.
View the full exondys 51 market report:
https://thebusinessresearchcompany.com/report/exondys-51-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Healthcare spending increases bolster market prospects
Rising financial commitments to healthcare are anticipated to play a key role in supporting Exondys 51 market growth. These investments cover funding for technologies, services, and innovations aimed at improving chronic disease management, particularly in aging populations. Additional resources are being directed toward advanced tools such as telemedicine to enhance care delivery. This influx of capital helps support exon-skipping research, clinical trials, and the infrastructure needed to expand patient access to therapies like Exondys 51. For example, in May 2024, the UK’s Office for National Statistics reported that healthcare spending climbed 5.6% in nominal terms from 2022 to 2023 — a notable jump from the 0.9% growth seen the previous year. That surge in funding is a critical factor underpinning the market’s expansion.
Regional outlook: North America leads, Europe accelerates
As of 2025, North America holds the largest share of the global Exondys 51 market, supported by sophisticated healthcare systems and favorable regulatory frameworks. Europe, however, is projected to post the fastest growth in the coming years, driven by heightened research activity and investment in genetic therapies. The market analysis also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa, with each region contributing distinct dynamics to the overall landscape.
What’s new in our 2026 market reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As DMD remains incurable and patient numbers hold steady, therapies like Exondys 51 represent a practical bridge between symptomatic care and future gene-based cures. The report’s findings suggest that sustained healthcare investment and diagnostic advances will keep this market expanding — a signal for stakeholders tracking rare disease treatment access.
